Mimura Masashi, Ueki Mari, Oku Hidehiro, Sato Bunpei, Ikeda Tsunehiko
Department of Ophthalmology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki City, Osaka, 569-8686, Japan,
Jpn J Ophthalmol. 2015 Jul;59(4):266-72. doi: 10.1007/s10384-015-0381-5. Epub 2015 Apr 28.
To study the indications for and effectiveness of Nunchaku-style silicone tube intubation (NSTI) in treating primary acquired lacrimal drainage obstruction (PALDO).
In this interventional cohort study, 235 consecutive patients in 1 institution who had complete lacrimal obstruction were investigated. Of those, 212 PALDO patients were enrolled, and 156 of the PALDO patients ultimately satisfied our treatment protocol and were then followed up for 12 months postsurgery. Patients without dacryocystitis underwent NSTI, while those with dacryocystitis underwent NSTI or endonasal dacryocystorhinostomy (EN-DCR) using the NST as a stent. The tubes were left in place for 8 weeks, and all patients received identical postoperative care. Resolution was deemed as patency assessed by irrigation. Logistic regression analyses were performed to compare the success of NSTI for upper (puncta and canaliculus) and lower (lacrimal sac and nasolacrimal duct) obstruction, NSTI for lower obstruction with and without dacryocystitis, and NSTI and EN-DCR for lower obstruction with dacryocystitis.
Comparison of the success rates at 12 months postsurgery showed significance as follows: treatment with NSTI was more successful for upper obstruction (94.6%) than for lower obstruction (71.4%) [odds ratio (OR) 8.23; P < 0.01]; treatment with NSTI was more successful for lower obstruction without dacryocystitis (82.9%) than for dacryocystitis (52.4%) (OR 4.96; P < 0.05); and treatment with EN-DCR (95.5%) was more successful than NSTI (52.4%) for treating lower obstruction with dacryocystitis (OR 16.99; P < 0.001).
NSTI is effective for treating PALDO; however, EN-DCR is more effective for treating PALDO cases complicated by dacryocystitis.
研究双节棍式硅胶管插管术(NSTI)治疗原发性获得性泪道阻塞(PALDO)的适应证及有效性。
在这项干预性队列研究中,对某机构连续235例存在完全性泪道阻塞的患者进行了调查。其中,212例PALDO患者被纳入研究,156例PALDO患者最终符合我们的治疗方案,随后在术后进行了12个月的随访。无泪囊炎的患者接受NSTI治疗,而有泪囊炎的患者接受NSTI或以内置NST作为支架的鼻内镜下泪囊鼻腔吻合术(EN-DCR)。硅胶管留置8周,所有患者术后接受相同的护理。通畅定义为冲洗评估通畅。进行逻辑回归分析以比较NSTI治疗上泪道(泪点和泪小管)和下泪道(泪囊和鼻泪管)阻塞的成功率、NSTI治疗下泪道阻塞伴和不伴泪囊炎的成功率以及NSTI和EN-DCR治疗下泪道阻塞伴泪囊炎的成功率。
术后12个月成功率比较显示差异有统计学意义,如下:NSTI治疗上泪道阻塞(94.6%)比下泪道阻塞(71.4%)更成功[比值比(OR)8.23;P < 0.01];NSTI治疗无泪囊炎的下泪道阻塞(82.9%)比有泪囊炎的下泪道阻塞(52.4%)更成功(OR 4.96;P < 0.05);对于治疗伴有泪囊炎的下泪道阻塞,EN-DCR(95.5%)比NSTI(52.4%)更成功(OR 16.99;P < 0.001)。
NSTI治疗PALDO有效;然而,EN-DCR治疗合并泪囊炎的PALDO病例更有效。